We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

T-Cell CD27 Expression Assessed for Smear-Negative Tuberculosis

By LabMedica International staff writers
Posted on 27 Jul 2021
Mycobacterium tuberculosis (MTB) and its related disease tuberculosis (TB) are infectious diseases with a worldwide focus. Although both vaccines and anti-TB drugs are available, there is a global focus on illness diagnosis in smear-negative and latent tuberculosis infectious populations (SN-TB and LTBI).

To a great extent, the cell-mediated immune response is involved in and regulates MTB, and CD4 T cells are thought to play a significant role in controlling MTB infection. CD27, a member of the TNF-receptor superfamily, is inextricably expressed on the mature pathogen-specific CD4+ T cell surface.

Image: The Cytomics FC500 Flow Cytometer System (Photo courtesy of Beckman Coulter Life Sciences)
Image: The Cytomics FC500 Flow Cytometer System (Photo courtesy of Beckman Coulter Life Sciences)

Pathogen Biologists at Nantong University (Nantong, China) and their colleagues include in a study 56 SN-TB patients, all had negative detection of sputum at least three times and sputum negative-culture results; an human control (HC) group that included 34 participants with no exposure to MTB and no clinical characteristics of TB, and the Tuberculosis Skin Test (PPD) test was negative; and 46 doctors and nurses working closely with TB patients for at least 1 year (TB-C group.)

All 56 smear-negative TB patients included in the study had peripheral blood collected and sputum collected at least three times for Ziehl-Neelsen acid-fast stain. Sputum culture was carried out by BACTEC MGIT 960 (Becton Dickinson, Sparks, MD, USA), liquid culture isolates using the GenoTypeH test system (Hain Lifescience, Nehren, Germany) and improved L-J culture medium. T-SPOT (tuberculosis infectious T-lymphocyte spot assay, Oxford Immunotec, Abingdon, UK) results were obtained from the clinical laboratory. For detection of the whole blood cell surface markers “CD27−CD4+” T cells, cells were collected, washed and analyzed by a Beckman Coulter FC500 flow cytometry analysis system (Indianapolis, IN, USA).

The scientists observed that the percentages of “CD27−IFN-γ+CD4+” cells were significantly increased in the SN-TB group compared with the HC and TB-C groups (AUC was 0.88, sensitivity was 82.14%, and specificity was 80.0%). The percentage of “CD27−IFN-γ+CD4+” cells was negatively correlated with white blood cell count (WBC) and positively correlated with immunoglobulin E (IgE). Furthermore, “CD27−IFN-γ+CD4+” cells were significantly decreased, especially in the > 50 years group, after clinical treatment.

The authors concluded that they had demonstrated the increased expression of “CD27−IFN-γ+CD4+” cells in smear-negative TB patients and evaluated its changes after normal anti-TB therapy. These data suggested that “CD27−IFN-γ+CD4+” T cells could be used to assist the diagnosis of TB and more accurately evaluate the treatment outcome of smear-negative TB. The study was published on June 27, 2021 in the journal BMC Immunology.

Related Links:
Nantong University
Becton Dickinson
Hain Lifescience
Oxford Immunotec
Beckman Coulter



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Immunology News

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment